Eptinezumab Trial for Pediatric Migraine Participants Initiated by Lundbeck
A clinical trial is underway to evaluate the efficacy of eptinezumab in reducing episodic migraine days in pediatric patients.
Asset / Drug
Drug and asset intelligence for Lundbeck with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.